Murchinson’s Relay Therapeutics RLAY Stock Holding History

Murchinson’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,000	Closed	-$26.2K	–	92
2025 Q1	$26.2K	Buy	+10,000	New	+$39.2K	﹤0.01%	96

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Murchinson's RLAY Position: Q2 2025 in Review

Murchinson sold out of Relay Therapeutics (RLAY) in Q2 2025, closing a stake of 10,000 shares — an estimated $26.2K sold.

Murchinson first reported a position in RLAY in Q1 2025 and held it in 1 quarter. The position peaked at $26.2K in Q1 2025. 208 funds tracked by Wall St. Rank hold RLAY as of Q2 2025.

Murchinson reported no remaining Relay Therapeutics position as of Q2 2025 after selling out during the quarter.
Murchinson sold 10,000 Relay Therapeutics shares in Q2 2025, an estimated $26.2K.
Murchinson first reported a position in Relay Therapeutics in Q1 2025 and held it in 1 quarter.
Murchinson's Relay Therapeutics position peaked at $26.2K in Q1 2025.
208 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2025.

Based on Murchinson's 13F filing for Q2 2025, filed 14 Aug 2025.